Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
Key Highlights
- ➤TAVR cut death or heart failure events 33% versus surveillance at two years
- ➤Heart failure hospitalizations fell to 7.4% with TAVR versus 14.9% under surveillance
- ➤TAVR produced a 15.5-point quality-of-life improvement at 30 days
- ➤27% underwent delayed valve replacement within one year under surveillance
- ➤PROGRESS trial enrolled 744 moderate AS patients with at-risk features across 74 sites
Expert Statements
Philippe Généreux, Director of the Structural Heart Program at Atlantic Health Morristown Medical Center
“The PROGRESS Trial validates TAVR as a treatment strategy for moderate AS patients with at-risk features and challenges the longstanding assumption that these patients can be managed by passive clinical surveillance”
Philippe Généreux, Director of the Structural Heart Program at Atlantic Health Morristown Medical Center
“Taken together, the practice-changing PROGRESS and EARLY TAVR trials deepen our understanding of aortic stenosis and reinforce the patient benefits of a more proactive approach to disease management.”
Philippe Généreux, Director of the Structural Heart Program at Atlantic Health Morristown Medical Center
“The evidence is now clear that intervening earlier in the disease pathway avoids significant health decline and serious cardiovascular events.”
Dan Lippis, Corporate Vice President of TAVR at Edwards
“The PROGRESS Trial represents a paradigm shift in the way the clinical community considers and treats patients with moderate AS”
Dan Lippis, Corporate Vice President of TAVR at Edwards
“These findings build on Edwards’ decades-long commitment to generating rigorous clinical evidence that advances the understanding of the serious impact and unpredictable progression of aortic stenosis.”
Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
* TAVR delivered more than 30% reduction in the composite endpoint of death or heart failure event as compared with clinical surveillance; results published in NEJM
Get started
Create a free account to read the full story.